Ocuphire Presents APX3330 ZETA-1 Data at Clinical Trials at the Summit (CTS) 2023

Jun 12, 2023

Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 24, 2023

Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update

May 15, 2023

Ocuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023 and Eyecelerator

May 2, 2023

Ocuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical Programs

Apr 25, 2023

Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer

Apr 21, 2023

Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update

Mar 30, 2023

Ocuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual Meeting

Mar 23, 2023

Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings

Feb 16, 2023

Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of Mydriasis

Feb 13, 2023